Overview

Update
IPO / Stock
Went Public on Oct 11, 2012 / NASDAQ:ICPT
Total Equity Funding
$80M in 3 Rounds from 2 Investors
Headquarters:
New York, NY
Description:
Intercept Pharmaceuticals develops small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases.
Founders:
Categories:
Pharmaceutical, Health Care, Biotechnology
Website:
http://www.interceptpharma.com
Social:

Company Details

Update

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, a FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases. Intercept Pharmaceuticals, Inc. was founded in 2002 and is based in New York, New York.

Funding Rounds (4) - $418.4M

Update
DateAmount / RoundValuationLead InvestorInvestors
Apr, 2015$338.4M / Post Ipo Equity0
Aug, 2012$30M / Series C1
Jan, 2010$25M / Series B0
Jul, 2008$25M / Series A1

Investors (2)

InvestorRound(s)Partner(s)
Series A (Lead)-
Series C (Lead)

Current Team (4)

Update

Offices/Locations (1)

Update
  • Headquarters

    18 Desbrosses Street

    New York, NY 10013

    USA

Images (2)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos